THE ULTRAN GROUP, INC. — Department of Defense SBIR Phase I: SB173-001

Description

Ultran will develop and prototype the transducer technology and initial system prototypes for a wearable system for imaging and modulation of peripheral nerves. Transducers developed for energy delivery will use Ultran's gas matrix piezoelectric (GMP) technology while those for imaging may use either GMP and piezoelectric micromachined ultrasonic transducers prototyped by a supplier. Miniaturized systems will be engineered and fabricated and then integrated with the transducer prototypes. Dr. Hubert Lim from The University of Minnesota will use developed prototypes in upcoming preclinical trials for the DARPA ElectRx program to advance research using ultrasound to modulation the spleen for the purpose of controlling inflammation. Dr. Lim’s collaboration with Ultran will provide the basis for development of a commercial system suited for spleen stimulation with a wearable device. In addition, Ultran will consider the use of the wearable system for minimally invasive neuromodulation using an implanted energy harvester for electrical stimulation. This allows for injection of a miniaturized implant at numerous peripheral nerve target sites. Following successful technical and clinical feasibility, Ultran will develop the technology and products and complete the clinical work to obtain FDA approval within 36 months upon completion of the Phase I base and option periods.